![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Zogenix Scoops Up FDA Fast Track Status for ZX008
Zogenix Scoops Up FDA Fast Track Status for ZX008
![](https://www.fdanews.com/ext/resources/test/Device_Images4/FDA_Logo_Large.gif?t=1486528488&width=430)
January 25, 2016
The FDA has fast tracked Zogenix’s ZX008 to treat seizures associated with Dravet syndrome, a rare form of childhood epilepsy.
The designation qualifies Zogenix for more communication with the agency and a potentially quicker review and approval process. Zogenix notes that a second Phase 3 study of ZX008 will begin in Europe this quarter.
Upcoming Events
-
21Oct